$3 million milestone payment for Chinese approval of OLINVYK® (oliceridine) injection
The Company also eligible to receive $15 million non-dilutive financing tranche from R-Bridge upon first commercial sale in China
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has received a $3 million milestone payment from its partner in China for the Chinese approval of OLINVYK. Jiangsu Nhwa Pharmaceutical Co. Ltd. (Nhwa) holds an exclusive license agreement to develop, manufacture, and commercialize OLINVYK in China.
https://finance.yahoo.com/news/trevena-announces-receipt-milestone-payment-110000896.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.